Get the Stockscreener App
1.36
0.74%
0.01
After Hours:
1.36
Metagenomi Therapeutics Inc stock is traded at $1.36, with a volume of 162.01K.
It is up +0.74% in the last 24 hours and down -9.33% over the past month.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
See More
Previous Close:
$1.35
Open:
$1.35
24h Volume:
162.01K
Relative Volume:
0.78
Market Cap:
$51.20M
Revenue:
$25.21M
Net Income/Loss:
$-87.87M
P/E Ratio:
-0.577
EPS:
-2.357
Net Cash Flow:
$-89.47M
1W Performance:
+8.80%
1M Performance:
-9.33%
6M Performance:
-19.53%
1Y Performance:
-16.05%
1-Day Range:
$1.28
$1.37
1-Week Range:
$1.25
$1.375
52-Week Range:
$1.24
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Name
Metagenomi Therapeutics Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.36 | 50.82M | 25.21M | -87.87M | -89.47M | -2.357 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Therapeutics Inc Stock (MGX) Latest News
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineQuarterly Earnings Report - Newser
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MSN Money - MSN
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy - TipRanks
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics: Q1 Earnings Snapshot - KVUE
Metagenomi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Metagenomi Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Metagenomi (NASDAQ: MGX) details Q1 2026 loss, cash runway and MGX-001 IND plans - Stock Titan
Metagenomi gene edit for hemophilia A targets 2027 human trials - Stock Titan
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
[DEF 14A] Metagenomi Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
MGX Price Today: Metagenomi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Metagenomi Therapeutics (MGX) Stock: Sentiment Analysis (Weakens) 2026-04-22Large Cap Trends - Xã Thanh Hà
MGX Financials: Income Statement, Balance Sheet & Cash Flow | Metagenomi Therapeutics, Inc - Stock Titan
A smaller gene editor cut Atxn2 protein 64% in mice, Metagenomi says - Stock Titan
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Eastern Progress
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency - The Manila Times
What is the valuation of Metagenomi Therapeutics (MGX) Stock | Price at $1.39, Up 0.72%Expert Market Insights - Newser
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
MGX: Metagenomi Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
If You Invested $1,000 in Metagenomi Therapeutics, Inc (MGX) - Stock Titan
Metagenomi Therapeutics Fiscal Results: Q4 Loss of $22.5M, Annual Loss $87.9MNews and Statistics - IndexBox
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics: Q4 Earnings Snapshot - kens5.com
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results - Bitget
Metagenomi Therapeutics Q4 Earnings Assessment - Benzinga
MGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MGX Technical Analysis & Stock Price Forecast - Intellectia AI
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference - The Manila Times
Metagenomi Therapeutics, Inc. CEO Jian Irish to Speak at 46th Annual TD Cowen Healthcare Conference - Quiver Quantitative
Gene-editing firm Metagenomi CEO in TD Cowen fireside chat - Stock Titan
MGXMetagenomi Therapeutics, Inc Latest Stock News & Market Updates - Stock Titan
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Head to Head Analysis: Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) - Defense World
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Metagenomi Therapeutics Inc Stock (MGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):